Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530
Debt
Debt-to-Equity RatioN/A
Current Ratio30.59
Quick Ratio30.60
Price-To-Earnings
Trailing P/E Ratio-17.70
Forward P/E Ratio-16.28
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.68 per share
Price / Book4.85
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-7,040,000.00
Net MarginsN/A
Return on Equity-40.86%
Return on Assets-38.75%
Miscellaneous
Employees3
Outstanding Shares18,930,000
Market Cap$155.82 million
Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions
What is Fennec Pharmaceuticals' stock symbol?
Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."
How were Fennec Pharmaceuticals' earnings last quarter?
Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Monday, August, 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.04. View Fennec Pharmaceuticals' Earnings History.
When is Fennec Pharmaceuticals' next earnings date?
What price target have analysts set for FENC?
3 brokerages have issued 1 year target prices for Fennec Pharmaceuticals' shares. Their forecasts range from $16.00 to $22.00. On average, they expect Fennec Pharmaceuticals' share price to reach $18.6667 in the next twelve months. This suggests a possible upside of 129.6% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals.
What is the consensus analysts' recommendation for Fennec Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.
What are Wall Street analysts saying about Fennec Pharmaceuticals stock?
Here are some recent quotes from research analysts about Fennec Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in pediatric patients. The Company's products include Eniluracil and Sodium Thiosulfate (STS). Fennec Pharmaceuticals Inc., formerly known as Adherex Technologies Inc., is based in United States. " (8/15/2018)
- 2. HC Wainwright analysts commented, "We remind investors that Fennec has guided towards the completion of the New Drug Application (NDA) submission to the FDA by late this year. In addition, we note that the agency previously granted PEDMARK (a unique formulation of sodium thiosulfate) the prized Breakthrough Therapy Designation (BTD) for prevention of cisplatin-related ototoxicity in pediatric patients with standard risk hepatoblastoma (SR-HB). There are currently no drugs approved in the U.S. for this condition. BTD is intended to facilitate development and expedite review of drugs to treat serious and life-threatening conditions for which there are no existing effective therapies. Given its Orphan Drug classification, BTD and Fast Track status, along with the unmet need in the pediatric oncology patient population, we continue to believe that PEDMARK could be approved in mid-2019 and launched in the U.S." (5/23/2018)
Who are some of Fennec Pharmaceuticals' key competitors?
Some companies that are related to Fennec Pharmaceuticals include Mesoblast (MESO), Vericel (VCEL), Voyager Therapeutics (VYGR), La Jolla Pharmaceutical (LJPC), Replimune Group (REPL), Novavax (NVAX), NanoString Technologies (NSTG), CASI Pharmaceuticals (CASI), Translate Bio (TBIO), Adverum Biotechnologies (ADVM), Cellular Biomedicine Group (CBMG), PDL BioPharma (PDLI), MeiraGTx (MGTX), Surface Oncology (SURF) and ADMA Biologics (ADMA).
Who are Fennec Pharmaceuticals' key executives?
Fennec Pharmaceuticals' management team includes the folowing people:
- Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
- Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
- Mr. Mark Gowland, Controller
- Mr. Lei Fang, Pres of Pharstat Inc
- Ms. Anne McKay, Regulatory Consultant (Age 64)
Has Fennec Pharmaceuticals been receiving favorable news coverage?
Media coverage about FENC stock has been trending somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Fennec Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Fennec Pharmaceuticals.
Who are Fennec Pharmaceuticals' major shareholders?
Fennec Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Opaleye Management Inc. (5.03%), BlackRock Inc. (2.95%), Northern Trust Corp (0.54%), Granahan Investment Management Inc. MA (0.30%), United Services Automobile Association (0.29%) and Cardinal Capital Management (0.14%). Company insiders that own Fennec Pharmaceuticals stock include Manchester Management Pr, Llc and Spa Essetifin. View Institutional Ownership Trends for Fennec Pharmaceuticals.
Which major investors are buying Fennec Pharmaceuticals stock?
FENC stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Opaleye Management Inc., Bank of New York Mellon Corp, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Bronfman E.L. Rothschild L.P. and Cardinal Capital Management. View Insider Buying and Selling for Fennec Pharmaceuticals.
How do I buy shares of Fennec Pharmaceuticals?
Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fennec Pharmaceuticals' stock price today?
One share of FENC stock can currently be purchased for approximately $8.13.
How big of a company is Fennec Pharmaceuticals?
Fennec Pharmaceuticals has a market capitalization of $155.82 million. The company earns $-7,040,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Fennec Pharmaceuticals employs 3 workers across the globe.
How can I contact Fennec Pharmaceuticals?
Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.
MarketBeat Community Rating for Fennec Pharmaceuticals (NASDAQ FENC)
MarketBeat's community ratings are surveys of what our community members think about Fennec Pharmaceuticals and other stocks. Vote "Outperform" if you believe FENC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FENC will underperform the S&P 500 over the long term. You may vote once every thirty days.
